Company news

ACADIA Pharmaceuticals Inc. news in 2025

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.

View company

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

December 17, 2025

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

December 11, 2025

Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

November 19, 2025

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

November 4, 2025

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

October 27, 2025

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 14, 2025

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 1, 2025

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

September 23, 2025

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

September 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 7, 2025

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

August 24, 2025

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

August 6, 2025

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 4, 2025

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

August 3, 2025

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

July 22, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

June 24, 2025

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

June 8, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

June 4, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 26, 2025

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 15, 2025

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 6, 2025

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

May 4, 2025

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

April 22, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

March 4, 2025

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

March 2, 2025

Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference

February 26, 2025

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

February 25, 2025

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

February 11, 2025

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

January 13, 2025

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025

Calls in 2025

Decks in 2025